title: Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
abstract: The potential predictive value of tumor bulk, genetic, and immunological variants in patients with low-grade non-Hodgkin's lymphoma to respond to treatment with rituximab (RTX) monotherapy was evaluated. Thus, the value of assessing the effect of 18-fluoro-desoxy-D-glucose (FDG) uptake on PET scan, polymorphisms in Fc gamma receptor (FcγR) IIIa-158, FcγRIIa-131, and C1qA-276 genes in predicting the response to treatment were evaluated in 50 low-grade non-Hodgkin's lymphoma patients. The influence of RTX pharmacokinetics, plasma levels of the B cell-activating factor (BAFF), and human antichimeric antibodies was also investigated. The therapeutic response was evaluated 10 weeks after treatment using revised Cheson's criteria. Lower maximal standardized uptake values (SUV(max)) at baseline were predictive of complete response. FcγRIIIa-158 polymorphism was also associated with complete response to RTX confirming previous findings, whereas polymorphisms in the FcγRIIa-131 and C1qA-276 genes were not. Lower blood levels of RTX were observed in males, but the effectiveness of RTX in males and females was the same. BAFF was not detectable in plasma before or after treatment, and no patients developed human antichimeric antibodies. Low-grade non-Hodgkin's lymphoma patients with a low SUV(max) at baseline and an FcγRIIIa-158 V/V genotype generally had a complete response to RTX.
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France.
authors.forename: Divi
authors.initials: D
authors.lastname: Cornec
authors.affiliation: Department of Clinical Oncology, Brest University Medical School Hospital, Brest, France.
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.affiliation: Unit of Nuclear Medicine, Brest University Medical School Hospital, Brest, France.
authors.forename: Solène
authors.initials: S
authors.lastname: Querellou
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Hutin
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Pers
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Jamin
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France.
authors.forename: Boutahar
authors.initials: B
authors.lastname: Bendaoud
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Department of Clinical Oncology, Brest University Medical School Hospital, Brest, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Renaudineau
authors.affiliation: EA2216 "Immunology and Pathology" and IFR146 "ScInBios", Université Européenne de Bretagne, Brest, France. youinou@univ-brest.fr.|Laboratory of Immunology, Brest University Medical School Hospital, BP824, Brest, 29609, France. youinou@univ-brest.fr.
authors.forename: Pierre
authors.initials: P
authors.lastname: Youinou
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000097:blood; D015922:Complement C1q / Q000235:genetics; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D060787:Neoplasm Grading; D009646:Norleucine / Q000031:analogs & derivatives / Q000097:blood; D011110:Polymorphism, Genetic; D049268:Positron-Emission Tomography; D011379:Prognosis; D017452:Receptors, IgG / Q000235:genetics; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D053264:B-Cell Activating Factor; C496124:FCGR3A protein, human; C080568:Fc gamma receptor IIA; D017452:Receptors, IgG; C505719:TNFSF13B protein, human; C001409:epsilon-hydroxynorleucine; D000069283:Rituximab; D015922:Complement C1q; D009646:Norleucine